Catherine M. Gordon

Study objectiveEstrogen replacement therapy (ERT) improves bone and neurocognitive health in adult women with premature ovarian insufficiency (POI). However, the response in adolescents is largely unknown. We aimed to assess the impact of t…

IntroductionGNAS mutations have been reported in both McCune-Albright syndrome (MAS) and juvenile granulosa cell tumors (JGCT) but have never been reported simultaneously in the same patient.Case presentationA 15-year-old girl developed sec…

Study objectiveTo explore the potential occurrence of long-term side effects and tolerability of gonadotropin-releasing hormone agonist (GnRHa) plus 2 different add-back regimens in adolescent patients with endometriosis.DesignFollow-up que…

Study objectiveUse of gonadotropin-releasing hormone agonists (GnRHa) to treat endometriosis can cause mood and vasomotor side effects. "Add-back therapy," the combination of low-dose hormones, limits side effects but research is limited to…

Endometriosis often begins during adolescence. Appropriate management includes prompt initiation of therapy and long-term maintenance therapy. Gonadotropin-releasing hormone (GnRH) agonists are commonly used second-line therapy for patients…

OBJECTIVE: To assess whether add-back therapy with norethindrone acetate or norethindrone acetate plus conjugated equine estrogens is superior to maintain bone health in adolescents and young women using gonadotropin-releasing hormone agoni…

Study objectiveTo evaluate the bone density of adolescents with endometriosis treated with a GnRH-agonist and "add-back" therapy with norethindrone acetate.DesignRetrospective chart review.SettingPediatric gynecology clinic at a tertiary ca…

OBJECTIVE: To review the impact of gonadotropin-releasing hormone agonists (GnRH-as) on bone mass in adolescents and options for GnRH-a with "add-back" for long-term therapy for adolescents with endometriosis not responding to conventional …